These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32561124)

  • 1. Does timing of intraperitoneal chemotherapy initiation following primary cytoreductive surgery with bowel resection impact outcomes in patients with advanced ovarian cancer?
    Nica A; Covens A; Parra-Herran C; May T
    Gynecol Oncol; 2020 Sep; 158(3):622-630. PubMed ID: 32561124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal ports placed at the time of bowel resection for treatment of ovarian cancer: Complications and surgical outcomes.
    Kay AH; Urban RR; Gray HJ
    Gynecol Oncol; 2019 Nov; 155(2):220-223. PubMed ID: 31488245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer.
    Chambers LM; Son J; Radeva M; DeBernardo R
    J Gynecol Oncol; 2019 Nov; 30(6):e93. PubMed ID: 31576687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National trends in bowel and upper abdominal procedures in ovarian cancer surgery.
    Dottino JA; He W; Sun CC; Zhao H; Fu S; Rauh-Hain JA; Suidan RS; Lu KH; Giordano SH; Meyer LA
    Int J Gynecol Cancer; 2020 Aug; 30(8):1195-1202. PubMed ID: 32616627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
    Schlappe BA; Mueller JJ; Zivanovic O; Gardner GJ; Long Roche K; Sonoda Y; Chi DS; O'Cearbhaill RE
    Gynecol Oncol; 2016 Jul; 142(1):13-18. PubMed ID: 27189456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
    Mueller JJ; Kelly A; Zhou Q; Iasonos A; Long Roche K; Sonoda Y; O'Cearbhaill RE; Zivanovic O; Chi DS; Gardner GJ
    Gynecol Oncol; 2016 Dec; 143(3):496-503. PubMed ID: 27692668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
    Gruner M; Chambers LM; Yao M; Chichura A; Morton M; Costales AB; Horowitz M; Rose PG; Debernardo R; Michener CM
    Gynecol Oncol; 2021 Sep; 162(3):645-651. PubMed ID: 34247768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
    Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
    J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery.
    Nasioudis D; Wang X; Dhillon G; Latif N; Ko EM; Giuntoli RL; Gershenson D; Fader A; Carey M; Simpkins F
    Int J Gynecol Cancer; 2023 Dec; 33(12):1906-1912. PubMed ID: 37879909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraperitoneal ropivacaine reduces time interval to initiation of chemotherapy after surgery for advanced ovarian cancer: randomised controlled double-blind pilot study.
    Hayden JM; Oras J; Block L; Thörn SE; Palmqvist C; Salehi S; Nordstrom JL; Gupta A
    Br J Anaesth; 2020 May; 124(5):562-570. PubMed ID: 32172954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer.
    Bartl T; Schwameis R; Stift A; Bachleitner-Hofmann T; Reinthaller A; Grimm C; Polterauer S
    Int J Gynecol Cancer; 2018 Nov; 28(9):1664-1671. PubMed ID: 30371563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
    Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
    Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.
    Estes JM; Leath CA; Straughn JM; Rocconi RP; Kirby TO; Huh WK; Barnes MN
    J Am Coll Surg; 2006 Oct; 203(4):527-32. PubMed ID: 17000397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of pre-existent bacterial colonization in patients with advanced/relapsed ovarian neoplasms undergoing cytoreductive surgery: a multicenter observational study (BONSAI).
    Fotopoulou C; Rinne N; Ghirardi V; Cunnea P; Drosou A; Tzovaras D; Giudice MT; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2020 Oct; 30(10):1562-1568. PubMed ID: 32817201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
    Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
    Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of interval between primary cytoreductive surgery with bowel resection and initiation of adjuvant chemotherapy on survival of women with advanced ovarian cancer: a multicenter cohort study.
    Lee YY; Kim SR; Kollara A; Brown T; May T
    J Gynecol Oncol; 2022 Nov; 33(6):e76. PubMed ID: 36047378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-duration antibiotics are not associated with a reduction in surgical site infection in patients with ovarian cancer undergoing cytoreductive surgery with large bowel resection.
    Chalif J; Chambers LM; Yao M; Kuznicki M; DeBernardo R; Rose PG; Michener CM; Vargas R
    Gynecol Oncol; 2024 Jul; 186():161-169. PubMed ID: 38691986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
    Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
    Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
    Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.